An expert on metastatic breast cancer provides clinical insights gleaned from the HER2CLIMB-02 trial and discusses the design and rationale of the ongoing HER2CLIMB-05 study.
Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic
Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.
Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer
Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.
Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.
T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer
The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.
Strategizing ADC Use to Enhance Breast Cancer Outcomes
Paolo Tarantino, MD, PhD, discusses sequencing ADCs, managing cross-resistance, and understanding ADC composition for patients with breast cancer.